Teladoc Stock Takes Off On Strong Q2 Results: The Details
Portfolio Pulse from Adam Eckert
Teladoc Health Inc (NYSE:TDOC) reported better-than-expected Q2 results, with revenues of $652.4 million, beating estimates of $649.19 million, and an EPS loss of 40 cents, better than the estimated loss of 41 cents. Revenues were up 10% YoY, and adjusted gross margin increased to 70.8% from 69.2% YoY. The company expects Q3 revenue to be between $650 million and $675 million, and full-year 2023 revenue to be between $2.6 billion and $2.675 billion.
July 25, 2023 | 8:37 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Teladoc Health's better-than-expected Q2 results and positive outlook for Q3 and full-year 2023 could boost investor confidence and potentially drive the stock price up in the short term.
Teladoc Health's Q2 results exceeded estimates, which is typically a positive signal to investors. The company's positive outlook for Q3 and full-year 2023 further indicates strong performance, which could lead to increased investor confidence and a potential rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100